In the absence of recognized therapeutic options for metastatic CoM and with extensive evidence from cutaneous melanoma (with which CoM shares many characteristics), BRAF and PD‐1 inhibitors provide rational current treatment options. Here, BRAF is linked to cutaneous melanoma.